Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Quarterly Financial Performance and Results of Operations
MRK logo

Merck Reports $16.3 Billion Revenue Amid $9 Billion R&D Charge for Cidara Acquisition

MRK10-QFiling Date: 5/4/2026
Merck & Co., Inc.
Description

What this story covers

Merck's Q1 2026 results show 5% revenue growth to $16.3 billion, led by Keytruda's $8 billion sales. A $9 billion acquisition charge caused a $4.2 billion net loss, reflecting aggressive pipeline expansion and strategic investments.

Story snapshot

CompanyMerck & Co., Inc.
TickerMRK
VariantStandard detailed
Duration11:15
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001628280-26-029802
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in